Competition record
Elanco
Deep profile · 1 linked library matter
Elanco sells animal-health products, including flea-and-tick treatments stocked by pet retailers. A court preliminarily approved a $9.275 million settlement on 17 September 2026, with a final hearing set for 1 April 2027.
Overview
Elanco's pet lines sit on the same retail shelf as rival flea-and-tick spot-ons, collars, and chews. Retailers decide which brands get the display, often in exchange for discounts tied to how much of the category they buy.
On 17 September 2026 a court preliminarily approved a $9.275 million settlement. The alleged exclusivity discount at pet retailers would be dropped for five years if the settlement is finally approved.
Final approval has not happened. The hearing on 1 April 2027 is still ahead, so the five-year term and the money are not yet a finished order.
Competition footprint
Pet-retail shelf space is where an exclusivity discount would steer volume toward Elanco and away from rival flea-and-tick brands.
Dropping that discount for five years is a proposed condition, effective only if the court finally approves the deal.
The $9.275 million figure is the preliminarily approved amount, not a sum finally awarded.
Consumer & business angle
Pet owners pay the shelf price and do not see the retailer's discount schedule.
Rival flea-and-tick suppliers are the companies that would compete for that shelf if the exclusivity discount ends.
What to watch
- The final approval hearing on 1 April 2027.
- Whether the five-year drop of the exclusivity discount survives that hearing.
Markets
animal health · flea and tick products · flea and tick medication
Also known as: elanco animal health